Zobrazeno 1 - 10
of 14
pro vyhledávání: '"Hong-Mei Fang"'
Publikováno v:
Frontiers in Pharmacology, Vol 12 (2021)
Objective: The CAMEL clinical trial (412 patients were randomly assigned to either camrelizumab plus chemotherapy (n = 205) or chemotherapy alone (n = 207)) demonstrated that camrelizumab plus chemotherapy (CC) improved the overall survival time (OS)
Externí odkaz:
https://doaj.org/article/548f6f1020b5446d871972e60444e06e
Autor:
Liu-Cheng Li, Zhi-Hui Zhang, Wen-Cheng Zhou, Jie Chen, Hua-Qian Jin, Hong-Mei Fang, Qin Chen, Ye-Cheng Jin, Jiao Qu, Lian-Di Kan
Publikováno v:
Biomedicine & Pharmacotherapy, Vol 130, Iss , Pp 110641- (2020)
Background: An outbreak of Coronavirus Disease 2019 (COVID-19) which was infected by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), is still spreading and has led to unprecedented health emergency over the world. Though no specific dru
Externí odkaz:
https://doaj.org/article/642e931764d4412ea03723e7a55c4246
Publikováno v:
International clinical psychopharmacology. 36(5)
Background Parkinson's disease (PD) is a neurological disorder involving both motor and nonmotor symptoms. Multimorbidity acts synergistically to heighten the risk of adverse outcomes for patients with PD. Its complications have a major impact on the
Autor:
Wencheng Zhou, Liu-Cheng Li, Zhi-Hui Zhang, Jiao Qu, Yong-Yue Han, Hong-Mei Fang, Lian-Di Kan
Publikováno v:
Drug Design, Development and Therapy
Chronic obstructive pulmonary disease (COPD) is the fourth leading cause of death across the globe. Its repeated exacerbation will seriously worsen the quality of life, aggravate the patients’ symptoms, and bring a heavy burden on the patients and
Publikováno v:
Clinical therapeutics. 43(3)
Purpose For the treatment of cerebral edema, the use of glycerol, an osmotic agent, as well as mannitol, is popular in Asia. However, the relative therapeutic benefit of glycerol remains unknown. The goal of this study was to investigate the comparat
Autor:
Yang Qiu, Jie Chen, Xin-Lu Yu, Liu-Cheng Li, Yue-Ting Huang, Qin Chen, Hong-Mei Fang, Lian-Di Kan
Publikováno v:
Clinical and experimental medicine. 20(4)
To evaluate the efficacy and economics of different proton pump inhibitors (PPIs) combined with bismuth quadruple regimens for Helicobacter pylori (Hp) eradication, a retrospective analysis method was used to collect Hp-positive patients who were tre
Autor:
Hai-juan Lv, Xue-ying Wang, Rong-fang Ma, Chen-yu Xue, Hong-mei Fang, Yuan Zhang, Guo-wen Xing, Gui-jun Zhang
Publikováno v:
Tetrahedron Letters. 57:4624-4628
3-AminoBODIPY derivatives ( 5a – e ) were unexpectedly synthesized by the coupling of amines with 2-BODIPY-borates in the presence of copper(II) acetate Cu(OAc) 2 and tetramethylethylenediamine (TMEDA) in the air at room temperature. 5a (p K a = 9.
Autor:
Jie Chen, Hong-Mei Fang, Lian-Di Kan, Qin Chen, Liu-Cheng Li, Hua-Qian Jin, Ye-Cheng Jin, Jiao Qu, Wencheng Zhou, Zhi-Hui Zhang
Publikováno v:
Biomedicine & Pharmacotherapy
Biomedicine & Pharmacotherapy, Vol 130, Iss, Pp 110641-(2020)
Biomedicine & Pharmacotherapy, Vol 130, Iss, Pp 110641-(2020)
Graphical abstract
Highlights • COVID-19 has led to serious death and lacks treatment strategies. • Lianhua Qingwen is a commonly used Chinese patent medicine to treat viral infection. • Lianhua Qingwen has antiviral, anti-inflammatory and
Highlights • COVID-19 has led to serious death and lacks treatment strategies. • Lianhua Qingwen is a commonly used Chinese patent medicine to treat viral infection. • Lianhua Qingwen has antiviral, anti-inflammatory and
Publikováno v:
Biomedicine & Pharmacotherapy, Vol 123, Iss, Pp 109661-(2020)
Ovarian cancer is the most lethal gynecologic malignancy and the fifth most lethal cancer type overall in women. Ovarian cancer often presents genome instability, with almost half of the ovarian cancers harbor defects in one or more of the six DNA re
Publikováno v:
Acta Pharmacologica Sinica. 34:549-554
To investigate the relationship of fibroblast growth factor receptor 4 (FGFR4) gene polymorphisms with the response of Chinese patients with non-small cell lung cancer (NSCLC) to chemotherapy. A total of 629 patients with Stage III (A+B) or IV NSCLC,